A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation - Wikidata - wikimedia - TriplyDB

A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation

A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation

http://www.wikidata.org/entity/Q35535475

about

Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.Cancer drug delivery in the nano era: An overview and perspectives (Review)In vitro determination of the efficacy of scorpion venoms as anti-cancer agents against colorectal cancer cells: a nano-liposomal delivery approach.A Glycyrrhetinic Acid-Modified Curcumin Supramolecular Hydrogel for liver tumor targeting therapy.Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil.Multifunctional Liposomes for Image-Guided Intratumoral Chemo-Phototherapy.Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.

P2860

Q37536696-1F2D0409-5E36-42F2-8062-B0269C55404F Q38669454-B056D7C3-AFF6-4504-96AE-247A12A05EB1 Q38718535-63EFFC6A-154B-4C08-89D8-30C7FA7319FE Q41890555-29D45DA0-767B-47F5-BC4E-9144C830E9C9 Q43083731-ED923B1F-35FC-4F97-8A7C-34DFB0123D82 Q48145022-3FA0AAD7-9AE9-410F-8AB2-BF590A73C10E Q54967621-F71514EF-DAAA-4B38-9487-50C9A94FFBAF

P2860

A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation

http://www.wikidata.org/entity/Q35535475

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A novel glycyrrhetinic acid-mo ...... g and in vitro/vivo evaluation

@ast

A novel glycyrrhetinic acid-mo ...... g and in vitro/vivo evaluation

@en

type

label

A novel glycyrrhetinic acid-mo ...... g and in vitro/vivo evaluation

@ast

A novel glycyrrhetinic acid-mo ...... g and in vitro/vivo evaluation

@en

prefLabel

A novel glycyrrhetinic acid-mo ...... g and in vitro/vivo evaluation

@ast

A novel glycyrrhetinic acid-mo ...... g and in vitro/vivo evaluation

@en

P1433

Q35535475-C1642DA2-9BE9-4E15-98CE-4DAFA5B6C7FF

P1476

Q35535475-7EC90737-5D16-451D-AD8F-6DF84815C16F

P2093

Q35535475-0EE5329E-15DC-42E0-B300-BC66A559D523

Q35535475-39CF5EB9-5CDB-4AAB-A577-CF586CA008BB

Q35535475-5009F040-D912-4F0F-BCB6-4DDEBA94F65F

Q35535475-5720F41F-5E7D-467A-B7A4-B55DD06F6752

Q35535475-CD9988C0-1015-40B1-B67B-E8B0CE5B9FE3

P2860

Q35535475-14CD2E77-2E31-47E7-909D-EF9D9BD6F1DC

Q35535475-1B00CE35-6918-4B89-AD13-4170D5EB0B4E

Q35535475-1F7E2AF1-B134-46A2-A0A8-E6D4AAE12E4C

Q35535475-2223DF36-2BB0-41D8-95F5-268683E32926

Q35535475-329FBEE2-D93C-45FF-A77A-8A7699425EF4

Q35535475-4C475803-E468-49B5-B4FC-986D677F3D56

Q35535475-4F005923-79B2-46C4-94B5-444F07647058

Q35535475-5C6CAE24-474C-4A6B-A264-2DFA7B888365

Q35535475-5F3EB406-335F-4471-8B1B-41F98A06907D

Q35535475-60D965BE-F691-4867-B2C8-27069B2905A7

P304

Q35535475-6519F270-809D-4CBB-9AED-B4B2E2D25CD4

P31

Q35535475-43629B6F-5854-4017-941A-3A3814C97554

P356

Q35535475-85963077-3A97-4C1E-99AF-C6C877B0BAFE

P407

Q35535475-A3D7A9C7-D193-4D37-B135-B663ADA1E4DE

P478

Q35535475-1537434C-57C8-4006-85E5-75494A7BCF93

P577

Q35535475-BF28469D-EACD-4B64-9AE7-336D573517B0

P5875

Q35535475-75F759B7-C2D3-4900-A6A8-832156CA2E1F

P698

Q35535475-FE646465-C023-4D97-83BA-67B5DD26B75B

P932

Q35535475-75FA4DFE-2E7C-430F-A03E-5E5399C95232

P356

P1433

Drug Design, Development and Therapy

P1476

A novel glycyrrhetinic acid-mo ...... g and in vitro/vivo evaluation

@en

P2093

Hong Jiang

http://www.w3.org/2001/XMLSchema#string

Jingde Chen

http://www.w3.org/2001/XMLSchema#string

Yandong Li

http://www.w3.org/2001/XMLSchema#string

Yin Wu

http://www.w3.org/2001/XMLSchema#string

Yong Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Recent advances with liposomes as pharmaceutical carriers

Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers.

International Conference on Harmonisation; Stability Data Package for Registration Applications in Climatic Zones III and IV; Stability Testing of New Drug Substances and Products; availability. Notice.

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.

Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.

Treatment of metastatic pancreatic adenocarcinoma: a review.

Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum.

Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current.

P304

2265-2275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S81722

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276072018

http://www.w3.org/2001/XMLSchema#string

P698

25945038

http://www.w3.org/2001/XMLSchema#string

P932

4408971

http://www.w3.org/2001/XMLSchema#string